患有心房的患者不太可能受益于阿司匹林单疗法
Nan Wang1, Qiqi Hou2, Shouling Wu3
1Catheterization Unit, Tangshan Gongren Hospital, Tangshan, People's Republic of China.
International journal of general medicine
|May 27, 2024
概括
在心房 (AF) 患者的阿司匹林单疗法没有降低缺血事件风险,但增加了出血风险. 阿司匹林 (ASA) 治疗不太可能使AF患者受益.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿司匹林 (ASA) 是用于心血管疾病 (CVD) 的主要抗血小板疗法.
- 许多心房动 (AF) 患者使用ASA,需要了解其风险和益处.
研究的目的:
- 研究AF患者的ASA单疗与主要心脏和脑血管不良事件 (MACCE) 之间的关联.
- 为了确定ASA单一治疗是否减少AF患者的缺血事件或增加AF患者的出血事件.
主要方法:
- 850名AF患者的社区队列被分为ASA单疗法 (n=174) 和非ASA治疗 (n=676) 组.
- 临床终点包括心肌梗塞 (MI),缺血性中风 (IS) 和出血性中风 (HS).
- 卡普兰-梅尔曲线,Log等级测试和考克斯回归模型用于分析MACCE风险.
主要成果:
- 在7.2年的时间里,ASA治疗与降低MACCE或缺血性中风 (IS) 风险无关.
- 单独治疗ASA显着与出血性中风 (HS) 的风险增加有关 (HR:2.563,P=0.044).
- 累计MACCE发生率为ASA的19.88%,而非ASA的17.27% (P=0.511).
结论:
- 在AF患者中,ASA单疗并不能降低缺血事件的风险.
- 单独治疗ASA与更高的出血事件风险有关,特别是出血性中风.
- AF患者不太可能从阿司匹林单一治疗中获益.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
738
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
738
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823